Abivax outlines 2024 goals for obefazimod, a novel oral drug for inflammatory diseases
Abivax SA, a French biotech company listed on Euronext Paris and Nasdaq, is developing a new class of drugs that target the body’s own immune regulators to treat chronic inflammatory diseases. The company’s lead candidate, obefazimod, is in late-stage clinical…